

COMPANY OVERVIEW

Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD). The Company has successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a "turning ON" medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has initiated its Phase 3 clinical program for APL-130277, relying on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the Company intends to submit a new drug application near the end of 2016 or in early 2017.

RECENT NEWS

[Cynapsus Therapeutics Obtains Final Court Order and HSR Waiting Period Expires for Plan of Arrangement with Sunovion Pharmaceuticals](#)

Oct 18 2016, 9:08 AM EDT

[Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion Pharmaceuticals](#)

Oct 13 2016, 4:00 PM EDT

[ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of Arrangement](#)

Sep 28 2016, 7:27 PM EDT

NASDAQ: CYNA

Market Cap	\$502.42M
Last Price	\$40.4805
Day Range	\$ - \$
52-Week Range	\$10.54 - \$40.67

TSX: CTH (CAD)

Market Cap	\$663.99M
Last Price	\$53.50
52-Week Range	\$14.00 - \$53.67
Day Range	\$53.50 - \$53.50

MANAGEMENT TEAM

Anthony J. Giovinazzo

President & CEO, Director

Dr. Albert Agro

Chief Medical Officer

Thierry Bilbault

Chief Scientific Officer and Executive Vice President of CMC

Andrew Williams

Chief Operating Officer and Chief Financial Officer

Kristen Galfetti

VP Investor Relations & Corporate Communications

CYNAPSUS THERAPEUTICS INC.

828 Richmond Street West
Toronto, Ontario M6J 1C9
CA

INVESTOR RELATIONS

Kristen Galfetti
Vice President Investor Relations & Corporate Communications
T: (416) 703-2449 x246
kgalfetti@cynapsus.ca

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.